DRKS00015664已完成未知
Randomized, placebo-controlled, blindtrial to evaluate tolerability and impact on skin hydration, skin density, skin roughness and skin elasticity of ELASTEN®, a dietary supplement containing special collagen peptides, compared to placebo (without nutritive substances), including 72 female volunteers with healthy skin aged 35 years or older
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 35 Years 至 one（—）
- 性别
- Female
入选标准
- •(1) skin type: any, (2) Written informed consent of volunteers or legal guardian available, (3) Volunteers must be able to communicate with the investigator and to understand and follow requirement of the clinical trial
排除标准
- •(1) Severe or chronic skin inflammation, (2) Severe internal or chronic diseases, (3) Intake of drugs which can impair the skin reaction (e.g. glucocorticoids, antiallergics, immunomodulators), (4) Application of preparations or care products containing an active substance 7-10 days before study onset, (5) Severe allergies or ever occured serious adverse effects by cosmetic preparations, (6) Sunbathing or solarium visits during the study, (7) Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’sDisorderTourette’s DisorderMedDRA version: 20.0Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-002270-48-HUOtsuka Pharmaceutical Development & Commercialization, Inc.228
进行中（未招募）
不适用
A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.EUCTR2007-003289-16-NLTibotec Pharmaceuticals118
进行中（未招募）
1 期
A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.Hepatitis C virus (HCV)MedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2007-003289-16-FRTibotec Pharmaceuticals Ltd
进行中（未招募）
不适用
A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.EUCTR2007-003289-16-DETibotec Pharmaceuticals127
进行中（未招募）
1 期
A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or without peginterferon alpha-2a and ribavirin.Hepatitis C virus (HCV)MedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2007-003289-16-BETibotec Pharmaceuticals